The ConsiGma™ machine can run 500g of product in R&D, but can also run clinical trial, launch size, and any production batches. This allows manufacturers to reduce development time, dramatically reduce costs and bring products to market much faster. ConsiGma™ can do particle design and mimic any traditional batch granulation process with better, more consistent quality resulting from its ‘risk based approach’ to GMP. The granules have generally a better intra-granular porosity with better compressibility characteristics that help tablet presses run more efficiently at maximum speed with hardly any weight adjustments being required. ConsiGma is a continuous manufacturing platform with a modular design. It can incorporate different granulation techniques (e.g. wet granulation or roller compation) combined with measurement of critical quality attributes, compression (direct compression is also available), and even coating. Other benefits include: fast installation; fast return on investment; and low energy consumption to help manufacturers meet environmental obligations – all contributing to to lowest possible total cost of ownership.
GEA Pharma Systems, Columbia MD, 21045. www.niroinc.com or call 410-997-8700
INTERPHEX Puerto Rico Booth No. 601